Cytochrome P450 3A4 (CYP3A4) is a critical enzyme in the cytochrome P450 superfamily, predominantly expressed in the liver and intestine, where it plays a central role in the metabolism of xenobiotics, including ~50% of clinically used drugs. As the most abundant hepatic cytochrome P450 isoform, CYP3A4 is involved in the oxidation, hydrolysis, and reduction of diverse substrates, influencing drug efficacy, toxicity, and interactions. Antibodies targeting CYP3A4 are essential tools for studying its expression, localization, and activity in tissues, as well as for investigating interindividual variability caused by genetic polymorphisms, drug induction, or inhibition. These antibodies are widely used in techniques like Western blotting, immunohistochemistry (IHC), and enzyme-linked immunosorbent assays (ELISA) to quantify protein levels, assess tissue distribution, or monitor regulatory changes under experimental conditions. Polyclonal antibodies often provide higher sensitivity due to multiple epitope recognition, while monoclonal antibodies offer superior specificity. Validation of CYP3A4 antibodies typically includes testing in CYP3A4-expressing cell lines or tissues, with cross-reactivity checks against other CYP isoforms (e.g., CYP3A5). Research applications span pharmacology, toxicology, and personalized medicine, particularly in understanding drug-drug interactions, metabolic disorders, and optimizing therapeutic regimens. Commercial CYP3A4 antibodies are commonly raised in rabbits, mice, or goats, with immunogens derived from human CYP3A4 peptide sequences or recombinant proteins. Proper controls, such as knockout models or siRNA silencing, are critical to confirm antibody specificity in experimental settings.